<i>NTRK</i> Fusions in Central Nervous System Tumors: A Rare, but Worthy Target
The neurotrophic tropomyosin receptor kinase (<i>NTRK</i>) genes (<i>NTRK1</i>, <i>NTRK2</i>, and <i>NTRK3</i>) code for three transmembrane high-affinity tyrosine-kinase receptors for nerve growth factors (TRK-A, TRK-B, and TRK-C) which are mainly inv...
Main Authors: | , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-01-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/21/3/753 |
id |
doaj-494e864ba4244b758043e4e860e7e05a |
---|---|
record_format |
Article |
spelling |
doaj-494e864ba4244b758043e4e860e7e05a2020-11-25T01:38:58ZengMDPI AGInternational Journal of Molecular Sciences1422-00672020-01-0121375310.3390/ijms21030753ijms21030753<i>NTRK</i> Fusions in Central Nervous System Tumors: A Rare, but Worthy TargetAlessandro Gambella0Rebecca Senetta1Giammarco Collemi2Stefano Gabriele Vallero3Matteo Monticelli4Fabio Cofano5Pietro Zeppa6Diego Garbossa7Alessia Pellerino8Roberta Rudà9Riccardo Soffietti10Franca Fagioli11Mauro Papotti12Paola Cassoni13Luca Bertero14Pathology Unit, Department of Medical Sciences, University of Turin, 10126 Turin, ItalyPathology Unit, Department of Oncology, University of Turin, 10126 Turin, ItalyPathology Unit, Department of Medical Sciences, University of Turin, 10126 Turin, ItalyPediatric Onco-Hematology Unit, Department of Pediatric and Public Health Sciences, University of Turin, 10126 Turin, ItalyNeurosurgery Unit, Department of Neurosciences, University of Turin, 10126 Turin, ItalyNeurosurgery Unit, Department of Neurosciences, University of Turin, 10126 Turin, ItalyNeurosurgery Unit, Department of Neurosciences, University of Turin, 10126 Turin, ItalyNeurosurgery Unit, Department of Neurosciences, University of Turin, 10126 Turin, ItalyDepartment of Neuro-Oncology, University and City of Health and Science Hospital, 10126 Turin, ItalyDepartment of Neuro-Oncology, University and City of Health and Science Hospital, 10126 Turin, ItalyDepartment of Neuro-Oncology, University and City of Health and Science Hospital, 10126 Turin, ItalyPediatric Onco-Hematology Unit, Department of Pediatric and Public Health Sciences, University of Turin, 10126 Turin, ItalyPathology Unit, Department of Oncology, University of Turin, 10126 Turin, ItalyPathology Unit, Department of Medical Sciences, University of Turin, 10126 Turin, ItalyPathology Unit, Department of Medical Sciences, University of Turin, 10126 Turin, ItalyThe neurotrophic tropomyosin receptor kinase (<i>NTRK</i>) genes (<i>NTRK1</i>, <i>NTRK2</i>, and <i>NTRK3</i>) code for three transmembrane high-affinity tyrosine-kinase receptors for nerve growth factors (TRK-A, TRK-B, and TRK-C) which are mainly involved in nervous system development. Loss of function alterations in these genes can lead to nervous system development problems; conversely, activating alterations harbor oncogenic potential, promoting cell proliferation/survival and tumorigenesis. Chromosomal rearrangements are the most clinically relevant alterations of pathological <i>NTRK</i> activation, leading to constitutionally active chimeric receptors. <i>NTRK</i> fusions have been detected with extremely variable frequencies in many pediatric and adult cancer types, including central nervous system (CNS) tumors. These alterations can be detected by different laboratory assays (e.g., immunohistochemistry, FISH, sequencing), but each of these approaches has specific advantages and limitations which must be taken into account for an appropriate use in diagnostics or research. Moreover, therapeutic targeting of this molecular marker recently showed extreme efficacy. Considering the overall lack of effective treatments for brain neoplasms, it is expected that detection of <i>NTRK</i> fusions will soon become a mainstay in the diagnostic assessment of CNS tumors, and thus in-depth knowledge regarding this topic is warranted.https://www.mdpi.com/1422-0067/21/3/753central nervous systemgliomapediatric tumorsmolecular pathologyntrkgene fusiontargeted therapiesprecision medicine |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Alessandro Gambella Rebecca Senetta Giammarco Collemi Stefano Gabriele Vallero Matteo Monticelli Fabio Cofano Pietro Zeppa Diego Garbossa Alessia Pellerino Roberta Rudà Riccardo Soffietti Franca Fagioli Mauro Papotti Paola Cassoni Luca Bertero |
spellingShingle |
Alessandro Gambella Rebecca Senetta Giammarco Collemi Stefano Gabriele Vallero Matteo Monticelli Fabio Cofano Pietro Zeppa Diego Garbossa Alessia Pellerino Roberta Rudà Riccardo Soffietti Franca Fagioli Mauro Papotti Paola Cassoni Luca Bertero <i>NTRK</i> Fusions in Central Nervous System Tumors: A Rare, but Worthy Target International Journal of Molecular Sciences central nervous system glioma pediatric tumors molecular pathology ntrk gene fusion targeted therapies precision medicine |
author_facet |
Alessandro Gambella Rebecca Senetta Giammarco Collemi Stefano Gabriele Vallero Matteo Monticelli Fabio Cofano Pietro Zeppa Diego Garbossa Alessia Pellerino Roberta Rudà Riccardo Soffietti Franca Fagioli Mauro Papotti Paola Cassoni Luca Bertero |
author_sort |
Alessandro Gambella |
title |
<i>NTRK</i> Fusions in Central Nervous System Tumors: A Rare, but Worthy Target |
title_short |
<i>NTRK</i> Fusions in Central Nervous System Tumors: A Rare, but Worthy Target |
title_full |
<i>NTRK</i> Fusions in Central Nervous System Tumors: A Rare, but Worthy Target |
title_fullStr |
<i>NTRK</i> Fusions in Central Nervous System Tumors: A Rare, but Worthy Target |
title_full_unstemmed |
<i>NTRK</i> Fusions in Central Nervous System Tumors: A Rare, but Worthy Target |
title_sort |
<i>ntrk</i> fusions in central nervous system tumors: a rare, but worthy target |
publisher |
MDPI AG |
series |
International Journal of Molecular Sciences |
issn |
1422-0067 |
publishDate |
2020-01-01 |
description |
The neurotrophic tropomyosin receptor kinase (<i>NTRK</i>) genes (<i>NTRK1</i>, <i>NTRK2</i>, and <i>NTRK3</i>) code for three transmembrane high-affinity tyrosine-kinase receptors for nerve growth factors (TRK-A, TRK-B, and TRK-C) which are mainly involved in nervous system development. Loss of function alterations in these genes can lead to nervous system development problems; conversely, activating alterations harbor oncogenic potential, promoting cell proliferation/survival and tumorigenesis. Chromosomal rearrangements are the most clinically relevant alterations of pathological <i>NTRK</i> activation, leading to constitutionally active chimeric receptors. <i>NTRK</i> fusions have been detected with extremely variable frequencies in many pediatric and adult cancer types, including central nervous system (CNS) tumors. These alterations can be detected by different laboratory assays (e.g., immunohistochemistry, FISH, sequencing), but each of these approaches has specific advantages and limitations which must be taken into account for an appropriate use in diagnostics or research. Moreover, therapeutic targeting of this molecular marker recently showed extreme efficacy. Considering the overall lack of effective treatments for brain neoplasms, it is expected that detection of <i>NTRK</i> fusions will soon become a mainstay in the diagnostic assessment of CNS tumors, and thus in-depth knowledge regarding this topic is warranted. |
topic |
central nervous system glioma pediatric tumors molecular pathology ntrk gene fusion targeted therapies precision medicine |
url |
https://www.mdpi.com/1422-0067/21/3/753 |
work_keys_str_mv |
AT alessandrogambella intrkifusionsincentralnervoussystemtumorsararebutworthytarget AT rebeccasenetta intrkifusionsincentralnervoussystemtumorsararebutworthytarget AT giammarcocollemi intrkifusionsincentralnervoussystemtumorsararebutworthytarget AT stefanogabrielevallero intrkifusionsincentralnervoussystemtumorsararebutworthytarget AT matteomonticelli intrkifusionsincentralnervoussystemtumorsararebutworthytarget AT fabiocofano intrkifusionsincentralnervoussystemtumorsararebutworthytarget AT pietrozeppa intrkifusionsincentralnervoussystemtumorsararebutworthytarget AT diegogarbossa intrkifusionsincentralnervoussystemtumorsararebutworthytarget AT alessiapellerino intrkifusionsincentralnervoussystemtumorsararebutworthytarget AT robertaruda intrkifusionsincentralnervoussystemtumorsararebutworthytarget AT riccardosoffietti intrkifusionsincentralnervoussystemtumorsararebutworthytarget AT francafagioli intrkifusionsincentralnervoussystemtumorsararebutworthytarget AT mauropapotti intrkifusionsincentralnervoussystemtumorsararebutworthytarget AT paolacassoni intrkifusionsincentralnervoussystemtumorsararebutworthytarget AT lucabertero intrkifusionsincentralnervoussystemtumorsararebutworthytarget |
_version_ |
1725051127274143744 |